| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| 1g | |||
| Other Sizes |
| Targets |
The primary target of mRNA-Encapsulating Lipid Excipient 1 is not a biological receptor but rather the lipid nanoparticle formulation itself. As an ionizable lipid, it facilitates the encapsulation of mRNA and promotes endosomal escape after cellular uptake. The compound is designed to be used as an excipient in lipid nanoparticle formulations for mRNA delivery. Its function is to enable efficient delivery of mRNA therapeutics to target cells rather than to interact with a specific pharmacological target.
|
|---|---|
| ln Vitro |
In vitro activity of mRNA-Encapsulating Lipid Excipient 1 is assessed in lipid nanoparticle formulation studies. The compound is evaluated for its ability to encapsulate mRNA, protect it from degradation, and facilitate cellular uptake and endosomal escape. In cell-based assays, lipid nanoparticles formulated with this excipient are tested for mRNA delivery efficiency, protein expression levels, and cytotoxicity. The compound's performance is compared to other ionizable lipids in terms of transfection efficiency and formulation stability.
|
| ln Vivo |
In vivo activity of mRNA-Encapsulating Lipid Excipient 1 is evaluated in animal models for mRNA delivery and therapeutic efficacy. Lipid nanoparticles formulated with this excipient are administered via various routes including intravenous, intramuscular, or subcutaneous injection to assess mRNA expression, biodistribution, and therapeutic outcomes. The compound enables the delivery of mRNA to target tissues and cells, facilitating protein expression for vaccine or therapeutic applications.
|
| Enzyme Assay |
For non-cellular assays, mRNA-Encapsulating Lipid Excipient 1 is characterized by standard analytical techniques including HPLC, NMR, and mass spectrometry to confirm identity and purity. The compound can be evaluated in lipid nanoparticle formulation studies for particle size, polydispersity, encapsulation efficiency, and stability. Typical protocols involve mixing the lipid with other formulation components (helper lipids, cholesterol, PEG-lipids) and mRNA in appropriate solvents, followed by characterization using dynamic light scattering and other analytical methods. Purity is ≥98%.
|
| Cell Assay |
For in vitro cell-based studies, mRNA-Encapsulating Lipid Excipient 1 is used in lipid nanoparticle formulations for mRNA delivery. Cells are cultured under standard conditions and treated with mRNA-loaded lipid nanoparticles containing this excipient. mRNA delivery efficiency is assessed by measuring protein expression using reporter assays (e.g., luciferase or GFP), qPCR, or other detection methods. Cytotoxicity and cellular uptake are also evaluated. Appropriate controls including formulations without the excipient should be included.
|
| Animal Protocol |
For in vivo animal studies, mRNA-Encapsulating Lipid Excipient 1 is formulated into lipid nanoparticles and administered via various routes including intravenous, intramuscular, or subcutaneous injection. Dosing solutions are prepared according to established lipid nanoparticle formulation protocols. The compound is evaluated in animal models for mRNA delivery efficiency, protein expression, biodistribution, immunogenicity, and therapeutic efficacy. Dosing regimens and administration protocols follow approved animal welfare guidelines and institutional protocols.
|
| ADME/Pharmacokinetics |
mRNA-Encapsulating Lipid Excipient 1 has a molecular weight of 755.23 and molecular formula C44H86N2O5S. It appears as a liquid. Purity: ≥98%. The compound is a thiocarbamate-based ionizable lipid used as an excipient in mRNA-encapsulating lipid nanoparticles. Storage: should be stored under recommended conditions. The compound is for research use only.
|
| Toxicity/Toxicokinetics |
mRNA-Encapsulating Lipid Excipient 1 is for research use only and not for human consumption. Standard laboratory safety practices should be followed when handling this lipid excipient. Appropriate personal protective equipment including gloves and safety glasses should be worn. Specific LD50 values and detailed toxicological profiles have not been extensively reported for this novel lipid excipient.
|
| References | |
| Additional Infomation |
mRNA-Encapsulating Lipid Excipient 1 (CAS 2230647-37-5) is also known as Compound 2 and 4,4'-((((3-(dimethylamino)propyl)thio)carbonyl)azanediyl)dibutanoic acid di(pentadecan-8-yl) ester. It is a thiocarbamate-based ionizable lipid used as an excipient in mRNA-encapsulating lipid nanoparticles. The compound is used in the formulation of mRNA-based therapeutics and vaccines. No clinical trials or therapeutic approvals exist for the excipient itself.
|
| Molecular Formula |
C44H86N2O5S
|
|---|---|
| Molecular Weight |
755.2291
|
| Exact Mass |
754.625
|
| CAS # |
2230647-37-5
|
| PubChem CID |
135130532
|
| Appearance |
Colorless to light yellow liquid
|
| LogP |
15.2
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
41
|
| Heavy Atom Count |
52
|
| Complexity |
747
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCC(CCCCCCC)OC(=O)CCCN(CCCC(=O)OC(CCCCCCC)CCCCCCC)C(=O)SCCCN(C)C
|
| InChi Key |
HAWZMEVIHSUELL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C44H86N2O5S/c1-7-11-15-19-23-30-40(31-24-20-16-12-8-2)50-42(47)34-27-37-46(44(49)52-39-29-36-45(5)6)38-28-35-43(48)51-41(32-25-21-17-13-9-3)33-26-22-18-14-10-4/h40-41H,7-39H2,1-6H3
|
| Chemical Name |
pentadecan-8-yl 4-[3-(dimethylamino)propylsulfanylcarbonyl-(4-oxo-4-pentadecan-8-yloxybutyl)amino]butanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3241 mL | 6.6205 mL | 13.2410 mL | |
| 5 mM | 0.2648 mL | 1.3241 mL | 2.6482 mL | |
| 10 mM | 0.1324 mL | 0.6621 mL | 1.3241 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
